|
|
This section is specifically for journalists who wish to learn about Cephalon and its nine proprietary products in the United States.
For information about clinical development programs for current products and new compounds, view our pipeline.
|
PROVIGIL® Press Kit
|
|
PROVIGIL is Cephalon’s flagship product and a first-in-class wake-promoting agent for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA) and shift work sleep disorder (SWSD).
|
| Background Documents |
Multimedia Files |
|
|
|
|
NUVIGIL™ Press Kit
|
|
NUVIGIL is the single-isomer formulation of the active ingredient in PROVIGIL. It is a wake-promoting agent approved for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA), narcolepsy, and shift work sleep disorder (SWSD). NUVIGIL will launch once additional clinical data has been amassed; a comprehensive clinical development program is in progress.
|
|
GABITRIL® Press Kit
|
|
The first and only FDA-approved selective GABA reuptake inhibitor, GABITRIL is an adjunct therapy for the treatment of partial seizures associated with epilepsy.
|
|
FENTORA® FDA Advisory Committee (May 6, 2008) Media Kit
|
|
In early 2008, the U.S Food and Drug Administration (FDA) accepted the supplemental New Drug Application (sNDA) submitted by Cephalon for FENTORA® (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
The FDA will convene an advisory committee panel on May 6, 2008, to consider the application and data on the use of FENTORA beyond the initial indication for breakthrough pain in cancer patients.
|
Fact Sheets
|
|
Reference Literature
|
|
Corporate Statements
|
|
AMRIX® Press Kit
|
|
AMRIX, the most recent addition to Cephalon’s pain product line, is the first and only once-daily, extended release skeletal muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
|
| Background Documents |
Multimedia Files |
|
|
|
|
FENTORA® Press Kit
|
|
FENTORA is the first and only buccal (membrane on the inside of the cheek) tablet indicated for the management of breakthrough pain in opioid-tolerant patients with cancer, and the first tablet formulation of fentanyl approved for any use.
|
| Background Documents |
Multimedia Files |
|
|
|
|
ACTIQ® Press Kit
|
|
ACTIQ is Cephalon’s first pain treatment and the first prescription medication in the world approved for the treatment of breakthrough pain in opioid-tolerant cancer patients.
|
| Background Documents |
Multimedia Files |
|
|
|
|
TREANDA® Press Kit
|
|
TREANDA® (bendamustine HCl) for Injection is a novel chemotherapeutic agent for chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
|
| Background Documents |
Multimedia Files |
|
|
|
|
TRISENOX® Press Kit
|
|
TRISENOX is a treatment for patients with acute promyelocytic leukemia (APL) who have relapsed.
|
| Background Documents |
Multimedia Files |
|
|
|
|
Cephalon Oncology Clinical Development Press Kit
|
|
VIVITROL® Press Kit
|
|
VIVITROL is the first once-monthly injectable medication to treat patients with alcohol dependence who are able to abstain from alcohol in an outpatient setting prior to treatment initiation. VIVITROL should be part of a comprehensive management program that includes psychosocial support.
|
| Background Documents |
Multimedia Files |
|
|
|
|
|